Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Diabetic Retinopathy Treatment Market by Product & Data Validation, Analysis and Forecast 2022

 



(Medical-NewsWire.com, July 25, 2017 ) According to Publisher, the Global Diabetic Retinopathy Treatment market is expected to reach $10.24 billion by 2022. Rising prevalence of diabetics, increasing management financial support, change in lifestyle and global aging population are the factors driving the market growth. However, Lack of accurate diagnosis, a lack of skilled ophthalmologist coupled with poor infrastructure and extended approval time for drugs are hampering the growth of global diabetic retinopathy market. Increase in awareness of diabetic retinopathy treatment and improvement of patient monitoring are some of the major trends in the market. The two main stages of diabetic retinopathy are non-proliferated and proliferated. Proliferated diabetic retinopathy is the mainly insecure stage and has the risk of detachment into the vitreous leading to severe vision loss.

For more information @ http://www.reportsweb.com/diabetic-retinopathy-treatment-global-market-outlook-2015-2022

North America leads the global diabetic retinopathy market due to vast number of aging population. The Asia Pacific diabetic retinopathy market is expected to witness profitable growth over the estimated period due to the occurrence of unmet needs in the developing countries such as China and India. These countries are expected to be the fastest growing diabetic retinopathy markets in Asia-Pacific region.

Some of the key players in the market include Regeneron Pharmaceuticals Inc., ThromboGenics, Genentech, Bayer Healthcare, Alimera Sciences, Actavis PLC, BCN Peptides, Novartis AG, Ampio Pharmaceuticals, Kowa Group, Sirnaomics Incorporation, Abbott Laboratories Ltd, Glycadia Pharmaceuticals, Alcon Laboratories Inc. and Parexel International Corp.

Type of Treatments Covered:
- Intraocular Steroid Injection
- Vitrectomy
- Anti-Vascular Endothelial Growth Factor (VEGF) drug
- Laser Surgery

Disease Type Covered:
- Proliferative Diabetic Retinopathy (PDR)
- Non-Proliferative Diabetic Retinopathy (NPDR)
- Moderate
- Mild
- Severe

End Users Covered:
- Ophthalmic Clinics
- Ambulatory Surgical Centers
- Hospitals
- Other End Users

Request Sample Copy http://www.reportsweb.com/inquiry&RW0001216339/sample

Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- Rest of Asia Pacific
- Rest of the World
- Middle East
- Brazil
- Argentina
- South Africa
- Egypt

10 Company Profiling
10.1 Regeneron Pharmaceuticals Inc.
10.2 ThromboGenics
10.3 Genentech
10.4 Bayer Healthcare
10.5 Alimera Sciences
10.6 Actavis PLC
10.7 BCN Peptides
10.8 Novartis AG
10.9 Ampio Pharmaceuticals
10.10 Kowa Group
10.11 Sirnaomics Incorporation
10.12 Abbott Laboratories Ltd
10.13 Glycadia Pharmaceuticals
10.14 Alcon Laboratories Inc.
10.15 Parexel International Corp.
List of Tables

Make an enquiry: http://www.reportsweb.com/inquiry&RW0001216339/buying

ReportsWeb.com

Rajat Sahni

+1-646-491-9876

sales@reportsweb.com

Source: EmailWire.Com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC